Ecstasy - cool dope with long-lasting effects?;Ecstasy - kult dop med senfølger?

Tidsskrift for den Norske Laegeforening

Volumn 118, Issue 28, 1998, Pages 4384-4387

  Liberg, John Petter ^a   Hovda, Knut Erik ^a   Nordby, Gudmund ^a   Jacobsen, Dag ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE; PSYCHEDELIC AGENT;

ADOLESCENT; ADULT; ARTICLE; CASE REPORT; CHEMICALLY INDUCED DISORDER; CHEMISTRY; FEMALE; FEVER; HUMAN; SEIZURE;

3,4-METHYLENEDIOXYAMPHETAMINE; ADOLESCENT; ADULT; FEMALE; FEVER; HALLUCINOGENS; HUMANS; SEIZURES;

EID: 0032553146     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Kriminalpolitisentralen: http://www.sol.no/kripos/.
2. Ellis AJ, Wenden JA, Portmann B, Williams R. Acute liver damage and ecstasy ingestion. Gut 1996; 38:454-58.
3. Statens institutt for alkohol og narkotikaforskning. Årsrapport 1996 og 1997. Oslo: SIFA, 1996, 1997.
4. Webb E, Ashton CH, Kelly P, Kamali F. Alcohol and drug use in UK university students. Lancet 1996; 348: 922-5.
5. Sletten KL. Færre unge bruker ecstasy. Vårt Land 9.9.1998.
6. Kronstrand R. Identification of N-methyl-1-(3,4-methylenedioxy-phenyl)-2-butanamine (MBDB) in urine from drug users. J Anal Toxicol 1996; 20: 512-6.
7. Nichols DE. Differences between the action of MDMA, MBDB and the classic hallucinogens. Identification of a new therapeutic class: Entactogens. J Psychoact Drugs 1986; 18: 305-13.
8. Dowling GP, McDonough ET, Bost RO. «Eve» and «Ecstasy» - a report of five deaths associated with the use of MDEA and MDMA. JAMA 1987; 257: 1615-7.
9. Green R, Cross AJ, Goodwin GM. Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or «Ecstasy»). Psychopharmacology 1995; 119: 247-60.
10. Grinspoon L, Bakalar JB. Can drugs be used to enhance the psychotherapeutic process? Am J Psychother 1986; 40: 393-404.
11. Greer G. Using MDMA in psychotherapy. Advances 1985; 2: 57-62.
12. Peroutka SJ. Incidence of recreational use of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) on an undergraduate campus. N Engl J Med 1987; 317: 1542-3.
13. Henry JA, Jeffreys KJ, Dawlings S. Toxicity and death from 3,4-methylenedioxymethamphetamine («ecstasy»). Lancet 1992; 340: 384-7.
14. Steele T, McCann U, Ricaurte GA. 3,4-methylenedioxymethamphetamine (MDMA, «ecstasy»): pharmacology and toxicology in animals and humans. Addiction 1994; 89: 539-51.
15. Creighton FJ, Black DL, Hyde CE. «Ecstasy» psychosis and flash-backs. Br J Psychiatry 1991; 159: 713-5.
16. Whitaker-Azmitia PM, Aronsen TA. «Ecstasy» (MDMA)-induced panic. Am J Psychiatry 1989; 146: 119.
17. Benazzi F, Mazzoli M. Psychiatric illness associated with «ecstasy». Lancet 1991; 338: 1520.
18. Mørland J. Ecstasy - veien til ekstase eller fortvilelse? Tidsskr Nor Lægeforen 1997; 117: 2432-3.
19. Schmidt CJ, Wu L, Lovenberg W. Methylenedioxymethamphetamine: a potentially neurotoxic amphetamine analogue. Eur J Pharmacol 1986; 124: 175-8.
20. Schmidt CJ, Taylor VL. Depression of rat brain tryptophan hydroxylase following the acute administration of methylenedioxymethamphetamine. Biochem Pharmacol 1987; 36: 4095-102.
21. Series H, Lindefors N. Ecstasy - verkningar och toxicitet. Läkartidningen 1993; 90: 2648-52.
22. Scanzello CR, Hatzidimitriou G, Martello AL, Katz JL, Ricaurte GA. Serotonergic recovery after (+/-) 3,4-(methylenedioxy)-methamphetamine injury: observations in rodents. J Pharmacol Exp Ther 1993; 264: 1484-91.
23. Ricaurte GA, Martello AL, Katz JL, Martello MB. Lasting effects of (+/-) 3,4-methylenedioxymethamphetamine on central serotonergic neurons in the primate: neurochemical observations. J Pharmacol Exp Ther 1992; 261: 616-22.
24. McGuire P, Fahy T. Chronic paranoid psychosis after misuse of MDMA («ecstasy»). BMJ 1991; 302: 697.
25. Brown C, Osterloh J. Multiple severe complications from recreational ingestion of MDMA («ecstasy»), JAMA 1987; 258: 780-1.
26. Glennon RA, Yousif M, Patrick G. Discriminative stimulus properties of 1-(3,4-methylenedioxyphenyl)-2-aminopropane (MDA) analogs. Pharma Bioch Behavior 1988; 29: 443-9.
27. Downing J. The psychological and physiological effects of MDMA on normal volunteers. J Psychoactive Drugs 1986; 18: 335-40.
28. Peroutka SJ, Newman H, Harris H. Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users. Neuropsychopharmacol 1980; 18: 273-7.
29. McCann DU, Ricaurte, GA. Lasting neuropsychiatric sequelae of (+) methylenedioxymethamphetamine («ecstasy») in recreational users. J Clin Psychopharma 1991; 11: 302-5.
30. Robertsen A, Kowalczyk M, Gabrielsen AM, Jacobsen D. Amfetaminforgiftning. Tidsskr Nor Lægeforen 1998; 118: 4340-3.
31. Nielsen JCF, Nicholson K, Pitzner-Jørgensen BL, Unden M. Misbrug af ecstasy (3,4-metylendioxymetampetamin). Ugeskr Læger 1995; 157: 724-7.
32. 2-receptors. Br J Pharmacol 1985; 84: 743-53.
33. Bedford-Russell AR, Schwartz RH, Dawling S. Accidental ingestion of «ecstasy» (3,4-methylenedioxymethamphetamine). Arch Dis Child 1992; 67: 1114-5.
34. Chance MRA. Aggregation as a factor influencing the toxicity of sympathomimetic amines in mice. J Pharmacol Exper Ther 1946; 87: 214-9.
35. Chance MRA. Factors influencing the toxicity of sympathomimetic amines to solitary mice. J Pharmacol Exp Ther 1947; 89: 289-96.
36. Askew BM. Amphetamine toxicity in aggregated mice. J Pharm Pharmacol 1961; 13: 701-3.
37. Screaton GR, Singer M, Cairns HS, Trasher A, Sarner M, Cohen SL. Hyperpyrexia and rhabdomyolysis after MDMA («ecstasy») abuse. Lancet 1992; 339: 677-8.
38. Fahal IH, Sallomi DF, Yaqoob M, Bell GM. Acute renal failure after ecstasy. BMJ 1992; 305: 29.
39. Mattai SM, Davidson DC, Sills JA. Cerebral oedema after MDMA («ecstasy») and unrestricted water intake. BMJ 1996; 313: 689-90.
40. Ziporyn T. A growing industry and menace: Makeshrift laboratory's designer drugs. JAMA 1986; 256: 3061-3.
41. Ricaurte GA, Finnegan KT, Irwin I. Langston JW. Aminergic metabolites in cerebrospinal fluid of humans previously exposed to MDMA: preliminary observations. Ann NY Acad Sci 1990; 600: 699-710.
42. Tucker GT, Lennard MS, Ellis SW, Woods HF, Cho AK, Lin LY et al. The demethylenation of methylenedioxymethamphetamine («Ecstasy») by debrisoquine hydroxylase (CYP2D6). Biochem Pharmacol 1994; 47: 1151-6.
43. Johansson I, Yue Qy, Dahl ML, Heim M, Säwe J, Bertilsson L et al. Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine. Eur J Clin Pharmacol 1991: 40: 553-6.
44. Watson JD, Ferguson C. Hinds CJ, Skinner R, Coakley JH. Exertional heat stroke induced by amphetamine analogues. Does dantrolene have a place? Anaesthesia 1993; 48: 1057-60.
45. Foster PS, Hopkinson KC, Denborough MA. Effects of diltiazem, verapamil and dantrolene on the contractility of isolated malignant hyperpyrexia-susceptible human skeletal muscle. Clin Exp Pharmacol Physiol 1989; 16: 799-805.
46. Blank JW, Boggs SD. Successful treatment of an episode of malignant hyperthermia using a large dose of dantrolene. J Clin Anesth 1993; 5: 69-72.
47. Singarajah C, Lavies NG. An overdose of ecstasy. Anaesthesia 1992; 47: 686-7.